Jelicic, Jelena (56180044800)Jelena (56180044800)JelicicLarsen, Thomas Stauffer (35405235400)Thomas Stauffer (35405235400)LarsenFialla, Annette Dam (23134361200)Annette Dam (23134361200)FiallaBukumiric, Zoran (36600111200)Zoran (36600111200)BukumiricAndjelic, Bosko (6507067141)Bosko (6507067141)Andjelic2025-06-122025-06-122022https://doi.org/10.1016/j.clml.2022.07.006https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135591073&doi=10.1016%2fj.clml.2022.07.006&partnerID=40&md5=6fd3920254a46dee46a91f1757a2819fhttps://remedy.med.bg.ac.rs/handle/123456789/3221Over the years, a rising incidence of liver cirrhosis and lymphoma has been observed. Therefore, the risk of having cirrhosis as a comorbidity increases, thus challenging treatment approaches as data on the management of these patients is lacking. We performed a systematic review to summarize papers that analyzed patients with liver cirrhosis that occurred before and/or concomitantly to lymphoma. We identified 153 papers (230 patients) through Pubmed and/or Embase search. Publications comprised predominantly of case reports and/or case series. Most patients had HCV-related cirrhosis (62.6%), and aggressive lymphoma histology (59.6%). Data on liver status was available in 55.7% of all patients, with 46.1% having decompensated liver cirrhosis. These patients experienced more often treatment reductions and/or modifications, treatment side effects, and inferior survival than those with compensated cirrhosis (median 18 months vs. median not reached). Dose reductions and/or treatment modifications primarily due to concomitant liver disease were common. Moreover, liver toxicity was observed in 33.6% of patients with provided information on treatment side effects, ranging from mild toxicity to liver failure with fatal outcomes. Again, despite treatment modification/reduction, patients with decompensated liver cirrhosis developed hepatic toxicity more frequently than patients with compensated liver disease. Although patients suffering from cirrhosis and lymphoma can tolerate standard chemoimmunotherapy, a cautious multidisciplinary approach is needed to evaluate the risks and benefits. © 2022Child-Pugh scoreCirrhosisLiverLymphomaTreatment